Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study

(2014) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Research.

Full text not available from this repository.

Official URL:


The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200. mg/day) or placebo in addition to risperidone (maximum dose of 6. mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time×treatment interaction for negative . F(2.254,85.638)=59.046, P<0.001 general psychopathology . F(1.703,64.700)=6.819, P=0.001, and positive subscales . F(1.655,62.878)=5.193, P=0.012 as well as total PANSS scores . F(1.677,63.720)=28.420, P<0.001 were observed. The strongest predictors for change in negative symptoms were the treatment group (β=-0.94, t=-10.59, P<0.001) followed by the change in PANSS positive subscale (β=-0.185, t=-2.075, P=0.045). Side effect profiles of the two treatment regimens were not significantly different. Minocycline seems to be an efficacious and tolerable short-term add-on to risperidone for treatment of negative and general psychopathology symptoms of schizophrenia. © 2014 Elsevier Ireland Ltd.

Item Type: Article
Keywords: minocycline; placebo; risperidone; antiinfective agent; minocycline; neuroleptic agent; risperidone, abdominal pain; add on therapy; adult; adverse outcome; article; chronic disease; clinical article; clinical assessment; constipation; controlled study; diarrhea; dizziness; drowsiness; drug dose titration; drug efficacy; drug tolerability; dysphagia; Extrapyramidal Syndrome Rating Scale; fatigue; female; Hamilton scale; human; increased appetite; loss of appetite; male; middle aged; motor dysfunction; multicenter study; muscle rigidity; negative syndrome; neurologic disease; outcome assessment; Positive and Negative Syndrome Scale; priority journal; randomized controlled trial; rating scale; restlessness; sore throat; tachycardia; treatment duration; tremor; urine retention; xerostomia; young adult; double blind procedure; drug combination; psychological rating scale; psychology; schizophrenia; treatment outcome, Adult; Anti-Bacterial Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Minocycline; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome
Page Range: pp. 540-546
Journal or Publication Title: Psychiatry Research
Volume: 215
Number: 3
Identification Number: 10.1016/j.psychres.2013.12.051
Depositing User: مهندس جمال محمودپور

Actions (login required)

View Item View Item